The goal of this phase 1 double blind, randomized controlled trial is to determine the safety of chondroitin sulfate supplementation in the neonates with necrotizing enterocolitis. The main questions the study aims to answer are:
Is chondroitin sulfate safe to administer in the neonatal NEC population, and will it have a beneficial profile in the short term intestinal and long term neurodevelopmental sequelae of NEC? Researchers will compare all cause mortality, progression to surgery, systemic inflammatory markers, and long term neurodevelopmental outcomes in those NEC patients who receive chondroitin sulfate compared to those who receive milk or formula placebo.

开始日期2025-01-01

申办/合作机构

Indiana University

IRCT20170608034390N13

/ Recruiting临床2/3期IIT

Evaluating the efficacy of intra-articular injection of high molecular weight hyaluronic acid and Chondroitin on the knee performance of patients with plateau fracture after surgical fixation

开始日期2024-06-21

申办/合作机构

Shahid Beheshti University of Medical Sciences

CTRI/2024/02/062371

/ Recruiting临床3期

A randomized double-blind placebo controlled clinical study for the comparative evaluation of efficacy and tolerability of chondroitin sulfate in improving knee joint health in adult subjects with mild osteoarthritis - NIL

开始日期2024-02-09

申办/合作机构-

100 项与硫酸软骨素相关的临床结果

登录后查看更多信息

100 项与硫酸软骨素相关的转化医学

登录后查看更多信息

100 项与硫酸软骨素相关的专利（医药）

登录后查看更多信息

2,698

项与硫酸软骨素相关的文献（医药）

2025-08-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Highly selective peptide-based fluorescent probe with aggregation induced emission (AIE) for detection of chondroitin sulfate and its application in living cells and zebrafish imaging

Article

作者: Wang, Peng ; Pu, Chunmei ; Cao, Xinlin ; An, Yong ; Li, Shiyang ; Deng, Weiliang

Chondroitin sulfate (CS), as a kind of acid mucosaccharide with natural activity, has shown various physiological activities in human body due to its advantages of high biocompatibility, good degradability and little side effects. Herein, a novel and simple peptide probe (TPE-ASRH) based on tetraphenylethene (TPE) and tetrapeptide (Ala-Ser-Arg-His-NH₂) was designed and synthesized. TPE-ASRH displayed remarkable aggregation induced emission (AIE) characteristic in DMSO/water binary mixture. Based on electrostatic attraction, TPE-ASRH displayed highly selective and sensitive detection to chondroitin sulfate with large Stokes shift (156 nm), and the limit of detection (LOD) for chondroitin sulfate was calculated to be 0.11 nM based on 3σ/k. In addition, the colour change of TPE-ASRH was observed significantly from midnightblue to steelblue after adding chondroitin sulfate using naked eyes under 365 nm UV irradiation. Meanwhile, TPE-ASRH was able to achieve a rapid response to chondroitin sulfate (less than 30 s) with a pH response range of 3-12, which indicated that TPE-ASRH can detect chondroitin sulfate rapidly under physiological conditions. The response mechanism of TPE-ASRH to chondroitin sulfate was demonstrated using Zeta particle size and potential, UV-vis titration spectroscopy, FTIR spectra and CD spectroscopy. Most importantly, TPE-ASRH revealed the considerably low cytotoxic effects and good biological permeability, and was successfully applied to image chondroitin sulfate in living cells and zebrafish.

2025-06-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Tricarbonylrhenium(I) complexes with aggregation-induced phosphorescence emission (AIPE) properties: Application to the selective detection of heparin and its main contaminant

Article

作者: Serpentini, Charles-Louis ; Vanucci-Bacqué, Corinne ; Guilbaud, Valentine ; Bedos-Belval, Florence ; Fery-Forgues, Suzanne ; Benoist, Eric ; Deleuzière, Maëlle

Phosphorescent tricarbonylrhenium(I) complexes that are more emissive in the aggregate state than in solution could be very valuable probes for biological analyses, but their development is delicate. The present work focuses on the synthesis and spectroscopic study of three new complexes that differ by the nature of their positively charged substituent. The dissolved complexes were very weakly emissive. Due to electrostatic interaction and aggregation, they showed a strong aggregation-induced phosphorescence enhancement (AIPE) effect in the presence of heparin, a polyanionic macromolecule of biological interest, and a weaker effect in the presence of chondroitin sulfate, which contains fewer negative charges. The magnitude of the AIPE effect depended on the nature and number of the cationic groups borne by the complex. However, it was weaker than expected from the behavior of the parent neutral complex studied in a conventional acetonitrile/water system, which highlights the challenge of accurately predicting solid-state emission properties for this class of molecules. This work introduces rhenium(I) complexes in the field of AIPE-active probes for the detection of polyanionic biomolecules.

2025-06-01·Food Chemistry

Facile and green synthesis of nanocarriers from chondroitin sulfate-based and whey protein isolate with improved stability and biocompatibility for anthocyanins protection

Article

作者: Xiao, Wenbin ; Li, Gaoyang ; Fu, Fuhua ; Gao, Zhipeng ; Fu, Yanjiao ; Su, Zhipeng ; Huang, Lvhong ; Shan, Yang ; Li, Zixuan ; Guo, Jiajing ; Su, Donglin

Anthocyanins (ACNs) are widely used in the culinary, cosmetic, and biomedical industries owing to their potent bioactivities. However, the rapid degradation of ACNs in extreme environments is a major limiting factor for their physicochemical stability and bioactivity. This study reported a facile and environmental-friendly ACN embedding strategy using chondroitin sulfate (CS) and whey protein isolate (WPI) to prepare the CS/WPI@ACN complex. The encapsulation efficiency of CS/WPI@ACN reached up to 84.87 % when the CS-to-WPI mass ratio was 1:5, and the core-to-wall material ratio was 1:3. Molecular docking analysis revealed that the CS/WPI complex harbored a concave chamber, which was conducive for the embedding of small ACN molecules and promoting drug activity. The CS/WPI@ACN complex enabled sustained ACN release in the gastrointestinal tract in vitro. The CS/WPI@ACN complex was stable under ascorbic acid treatment conditions, high temperatures, and a wide range of pH levels. In vitro release data demonstrated that most encapsulated ACNs were released in the small intestine. Furthermore, the antioxidant activity of the CS/WPI@ACN complex was higher than that of free ACN. Therefore, this study proposed a strategy to protect unstable active substances, and laid a foundation for blueberry anthocyanins in the high-value utilization of functional drinks.

项与硫酸软骨素相关的新闻（医药）

2025-04-25

·美通社

汤臣倍健一季度双线出击：升级基础营养素、发力强功能产品

广州 2025年4月25日 /美通社/ -- 4月25日晚间，汤臣倍健（300146.SZ）发布2025年一季度报告。报告显示，2025年一季度汤臣倍健实现营业收入17.92亿元，归属于上市公司股东的净利润4.55亿元，同比均有所下滑。欧睿数据显示，2024年中国维生素与膳食补充剂行业零售规模同比增长约3.7%，较2023年的约11.6%明显收窄。线下渠道方面，中康CMH的数据显示，2025年1-2月全国零售药店VDS销售额延续了下跌趋势，同比下降19.1%。电商方面，行业规模扩张背后难掩盈利难题。2025年第一季度，VDS电商的销售额同比增长28%*，但获客成本高企、销售费用率增长等现实也成为商家的困扰。面对严峻的行业现状，汤臣倍健积极推动产品创新：聚焦广渗透、高频购买的基础营养素品类，推出高质比产品带动品类增量；针对不同场景和人群，优化强功能产品的功效体验，构建应对行业挑战的新解法。线下方面，汤臣倍健推出好吸收、少胀气的液体钙DK（120粒），上架后广受青睐。汤臣倍健CEO林志成透露，该单品原本预计全年销量为200万盒，一季度市场表现超预期，全年销量有望翻倍。汤臣倍健还将沿袭此单品的策略，打造维生素、益生菌等品类的明星单品。报告期内，汤臣倍健还在线下渠道推出了四重草本科学复配的健安适水飞蓟葛根丹参片8粒装，含有百倍精粹葛根素，活性成分葛根素加速酒精代谢，辅助保护化学性肝损伤。产品上市一个月，发货超25万盒，广受药店渠道欢迎。线上方面，汤臣倍健推出了更多功能突出的专业产品。4月初，汤臣倍健上线了电商专供的金装鱼油，产品纯度高达96%，全程锁鲜工艺做到一级新鲜好鱼油。上市半个月，金装鱼油带动汤臣倍健天猫官方旗舰店和京东自营旗舰店鱼油品类日均销售额增长20%并登顶京东食健字鱼油新品榜。 lifespace益倍适在跨境渠道推出拥有IFF全球独家金标配方的超燃B420益生菌新品。产品上市后，首个抖音专场直播开播1小时的销售额即破千万，登上抖音带货榜TOP1和热销商品排行榜TOP1。创新产品频出背后，是科研实力的加持。持续的科研投入，让汤臣倍健在今年一季度收获多项成果。报告期内，汤臣倍健联合北京大学第三医院发表重磅临床实证成果，证实健力多氨糖、硫酸软骨素、钙等组合物联合运动对中老年的膝关节炎人群的关节总体改善有效率高达70%；牵头起草的保健食品行业首个真实世界研究标准发布，且汤臣倍健健力多已在骨关节健康领域率先开展了万人级大规模真实世界研究，为标准在行业的推广提供了实证案例。今年一季度以来，除了面向国内行业现状构建解法，汤臣倍健也在探索海外新增量。汤臣倍健2025年将全面升级国际化业务，聚焦东南亚市场并率先在印尼市场部署试点。中国国际金融研报指出，2025年汤臣倍健继续优化线上和线下业务，收入增速环比有望逐渐改善，全年业绩同比有望保持相对平稳。在行业竞争加剧期，汤臣倍健展现出锐意进取的主动变革能力，液体钙DK的渠道适配经验与金装鱼油的高端化突破，展示了其基础营养素进阶和重功能产品专业创新双线策略的可行性。随着新品矩阵的落地和海外布局的提速，这家VDS龙头企业的长期价值有望进一步凸显。 *统计平台：阿里、京东、抖音、快手，数据来源：生意参谋、策略中心、商智、数坊、飞瓜

财报

2025-04-07

·PRNewswire

Clinical Study Shows Modulation of Ki-67 Markers by those taking Avmacol® in Former Smokers at High-risk for Lung Cancer

LANCASTER, S.C., April 7, 2025 /PRNewswire/ -- Nutramax Laboratories Consumer Care, Inc. is pleased to share the results of a newly published human clinical study by Yuan et al., in the Cancer Prevention Research journal. The study indicates that Avmacol®, an oral sulforaphane-producing supplement with glucoraphanin and active myrosinase enzyme, is safe and effective at reducing the number of cells with positive Ki-67 in bronchial biopsies in former smokers that are at high-risk for lung cancer. These results significantly add to the growing body of knowledge using Avmacol® as the study product, contributing to the #1 researched sulforaphane-producing brand^. Sulforaphane is an isothiocyanate widely studied for its' detoxification, cellular health, and antioxidant benefits. Sulforaphane is naturally created in the body with glucoraphanin and an active myrosinase enzyme. In this double-blind, placebo-controlled, randomized clinical study, 43 former smokers were assigned to either the sulforaphane (Avmacol®) or placebo group. Subjects in the sulforaphane group took 120 milligrams of glucoraphanin per day for 12 months. One of the primary targets included the Ki-67 index, which is a cancer proliferation marker. Results indicated a 20% decrease of Ki-67 in the sulforaphane group as compared to a 65% increase in the placebo group. "The promising results from this phase II clinical trial provides support for a phase III intervention trial with a large sample size and long-term period to directly examine the efficacy of lung cancer prevention by sulforaphane," said Dr. Jian-Min Yuan, principial investigator on this study from the University of Pittsburgh Medical Center Hillman Cancer Center. The ingredients to make sulforaphane in the body are found in Avmacol® and Avmacol® Extra Strength. The Avmacol® brand is the #1 researched sulforaphane-producing brand^. "This study adds to the rich body of scientific evidence in understanding the nutritional benefits of sulforaphane for targeted care in complex cases," said Meghan Hamrock, MS, MPH, Director of Consumer Marketing and Clinical Nutrition for Nutramax Laboratories Consumer Care, Inc. ABOUT NUTRAMAX LABORATORIES CONSUMER CARE, INC Nutramax Laboratories Consumer Care, Inc. is focused on researching and developing products to promote consumer health. Since its inception in 1992, the Christian-based company has been committed to developing high-quality products. Cosamin® is the #1 researched glucosamine/chondroitin sulfate brand and Avmacol® is the #1 researched sulforaphane-producing brand based on U.S. studies published in peer-reviewed journals. Our products are backed by science and manufactured in world-class facilities at our headquarters in Lancaster, South Carolina where we employ over 800 people nationwide. For more information, visit Avmacol.com or call Customer Service at 888-886-6442. ^ The Avmacol® brand has been selected for use in more sulforaphane human clinical trials than any other sulforaphane-producing supplement. SOURCE Nutramax Laboratories, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床2期临床3期

2024-10-20

·生物探索

Nature | 下丘脑神经纤维化驱动代谢性疾病的发生

引言胰岛素抵抗与外周组织的细胞外基质（ECM）重塑密切相关，过度的ECM沉积（即纤维化现象）会通过增加组织刚度，改变胰岛素在细胞膜受体上的结合效率，阻碍胰岛素信号的正常传播，进而加剧了胰岛素抵抗的程度【1】。传统上认为纤维化主要在脂肪组织、骨骼肌及肝脏等外周组织中发生，对代谢稳态产生至关重要的影响【2】。然而，近年来的研究揭示，纤维化不仅限于外周组织，在急性脑损伤和多种神经系统疾病中，也观察到了大脑内的ECM重塑现象【3】。最近研究表明，大脑特定区域中，尤其是下丘脑弓状核（ARC）中的ECM重塑可能与代谢调控密切相关。ARC是一个已知的控制食欲和能量代谢的关键区域，其中表达食欲相关肽（AgRP）的神经元在能量平衡中发挥了核心作用。在神经元成熟的过程中，AgRP神经元周围形成了一种特殊的ECM亚型——神经元周围网（PNNs）【4】。PNNs通过支持结构形成和调节微环境，直接影响AgRP神经元的功能，当PNNs结构受损时，AgRP神经元周围的纤维密度增加，同时伴随着细胞数量的变化，这体现了PNNs的完整性对于维持ARC神经元的代谢功能至关重要。此外，ARC及其附近区域的ECM重塑具有动态性，能够根据外界营养状况发生快速变化。这种可塑性反映了ECM在神经内分泌系统中的潜在作用，可能通过调节神经元与其微环境间的互作，影响代谢信号的传递和调控【5】。鉴于纤维化在外周组织中与细胞功能障碍之间的密切关联，ARC中的ECM重塑可能为理解代谢性疾病的发病机制提供全新视角。近日，墨尔本大学Garron T. Dodd实验室领衔在Nature杂志发表了题为Pathog enic hypothalamic extracellular matrix promotes metabolic disease的研究文章，发现高脂高糖饮食会导致下丘脑ARC中的PNN重塑，损害胰岛素信号，导致AgRP神经元功能异常及代谢紊乱。通过酶解PNN或使用氟氨糖抑制神经纤维化，可恢复胰岛素敏感性。此外，下丘脑炎症是驱动PNN重塑的关键因素，抑制炎症可有效缓解纤维化和代谢失调。通过WFA染色发现，在高脂高糖饮食下，小鼠下丘脑ARC区域的神经纤维化显著加剧，这一变化特异性发生在ARC区域，与代谢疾病的发生紧密相关。而在肥胖诱导的神经纤维化过程中，ARC中的PNN与ECM的组成发生了显著变化。透明质酸与WFA信号在ARC中几乎完全共定位，且在肥胖小鼠中其含量增加。此外，软骨素硫酸蛋白聚糖（CSPG）成分也在肥胖过程中显著增加，凝聚素增加与PNN的变化高度相关。因此，肥胖会促使ARC中多种主要ECM成分的增加，而凝聚素在神经纤维化中起着关键作用。 ARC包含两类与代谢密切相关的神经元群体：AgRP神经元和促黑皮质素原（POMC）神经元。正常条件下，大约45%的AgRP神经元和24%的POMC神经元被PNN包裹。而在代谢疾病发生过程中，AgRP神经元周围的PNN显著增加，并伴随着WFA和凝聚素的增强，可见代谢疾病的发展与ARC中AgRP神经元周围的神经纤维化密切相关。此外，PNNs被认为具有较慢的更新速率，然而作者发现在促肥胖饮食作用下，ARC中的PNN重塑和更新速度相对较快。为确定体内状态下PNN的更新速率，作者开发了基于“脉冲-追踪”技术的“PNN追踪器”，以标记感兴趣脑区的PNN变化。作者证明了“PNN追踪器”可以可靠地标记ARC中的PNN，并验证了WFA-生物素能够准确标记注射时存在的PNN。“PNN追踪器”数据表明ARC中的PNN更新周期约为五周，远快于其他脑区。此外，ARC中PNN的快速降解表明其在代谢调控中可能具有独特的生理功能，同时也显示了不同脑区在ECM更新方面存在显著差异。这为进一步研究脑区特异的PNN功能提供了重要线索。接下来作者验证了ARC中的神经纤维化是否是由于PNN降解减少所导致的，发现与瘦小鼠相比，肥胖小鼠的PNN降解速度显著减慢，并且与PNN相关的关键蛋白酶在肥胖小鼠中的表达减少。因此，PNN降解的减少导致了ARC中的神经纤维化，并推动了代谢疾病的进展。抑制ARC神经纤维化不仅降低了体重和脂肪含量，还增强了全身能量消耗和组织的热生成，改善了胰岛素敏感性和葡萄糖稳态，表明ARC神经纤维化在肥胖及代谢疾病的发生中起着关键作用。另一方面，作者发现肥胖引发的神经纤维化通过阻碍胰岛素进入下丘脑的ARC区域，导致胰岛素信号传导受损。通过注射软骨素酶ABC（chABC）选择性解构PNN，肥胖小鼠的ARC区域胰岛素信号得以恢复，而这并不依赖于体重的变化。此外，PNN中的葡萄糖胺聚糖的负电荷是胰岛素与PNN相互作用的关键，这为ARC神经纤维化在肥胖相关胰岛素抵抗中的作用提供了机制性解释。同时，这种现象特异于胰岛素，未对瘦素产生类似影响，表明ARC神经纤维化主要调节胰岛素的进入和信号传导。此外，ARC中的PNN通过调节AgRP神经元的电生理特性与能够胰岛素直接互作。肥胖状态下，神经纤维化导致AgRP神经元对胰岛素的响应减弱，从而加剧胰岛素抵抗。AgRP神经元中胰岛素受体的功能性信号对于代谢调节至关重要。通过CRISPR技术生成的小鼠模型显示，去除ARC神经纤维化能够恢复胰岛素信号，从而改善代谢健康和血糖控制。不仅如此，下丘脑炎性反应会影响细胞外基质重塑和整体的代谢功能。通过抗炎和促炎实验，作者确认了下丘脑炎症与神经纤维化之间存在明显的关联性，且下丘脑炎症促进病理性PNN重塑，这是全身代谢功能障碍的因果驱动因素。最后，作者探索了靶向神经纤维化的药理潜力，检测了CS-GAG链组装和延长酶的抑制剂——氟氨糖对神经纤维化和代谢的影响，发现氟氨糖作为一种小分子抑制剂，能够有效靶向神经纤维化，进而改善代谢健康。综上所述，本研究发现高脂高糖饮食会导致ARC中神经元周围的PNN重塑，进而引起胰岛素信号传导受损、AgRP神经元功能异常以及全身代谢失调。通过酶解PNN或者使用小分子抑制剂氟氨糖来靶向和逆转ARC中的神经纤维化，可以恢复胰岛素敏感性并缓解代谢紊乱。此外，本研究还揭示了下丘脑炎症作为驱动ARC中PNN重塑的诱因，通过抑制炎症可以显著抑制神经纤维化和代谢失调。未来研究中，研究人员可以进一步探索如何更精准地调控PNN重塑，并以此开发针对神经纤维化的药物，这将为肥胖和糖尿病等代谢性疾病的治疗带来新的希望。参考文献 1. Guglielmi, V. et al. Omental adipose tissue fibrosis and insulin resistance in severe obesity. Nutr. Diabetes 5, e175 (2015). 2. Berria, R. et al. Increased collagen content in insulin-resistant skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 290, E560–E565 (2006). 3. Shijo, T. et al. Aberrant astrocytic expression of chondroitin sulfate proteoglycan receptors in a rat model of amyotrophic lateral sclerosis. J. Neurosci. Res. 96, 222–233 (2018). 4. Mirzadeh, Z. et al. Perineuronal net formation during the critical period for neuronal maturation in the hypothalamic arcuate nucleus. Nat. Metab. 1, 212–221 (2019). 5. Kohnke, S. et al. Nutritional regulation of oligodendrocyte differentiation regulates perineuronal net remodeling in the median eminence. Cell Rep. 36, 109362 (2021). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41586-024-07922-y 责编|探索君排版|探索君文章来源|“BioArt” End 往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文 Cell | 是什么决定了细胞的大小？热文 Nature | 2024年值得关注的七项技术热文 Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文 CRISPR技术进化史 | 24年Cell综述

核酸药物

100 项与硫酸软骨素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	M01AX25	DB09301

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高脂血症	中国	成都市海通药业有限公司	1981-01-01
骨关节炎	-	IBSA Institut Biochimique SA	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
克罗恩病	申请上市	美国	University Hospitals Cleveland Medical Center	2011-01-01
膝关节炎	临床1期	波兰	IBSA Institut Biochimique SA	2014-06-12
膝关节炎	临床1期	瑞士	IBSA Institut Biochimique SA	2014-06-12
膝关节炎	临床1期	比利时	IBSA Institut Biochimique SA	2014-06-12
膝关节炎	临床1期	意大利	IBSA Institut Biochimique SA	2014-06-12
膝关节炎	临床1期	捷克	IBSA Institut Biochimique SA	2014-06-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCO_IOF_ESCEO2023	N/A	膝关节炎	35	Chondroitin Sulfate	廠艱遞構鹽選鑰餘淵壓(鬱鹹網範衊構艱鹽糧構) = 醖範鬱憲淵積壓窪壓遞淵簾窪醖憲築憲遞壓築 (製鬱構鬱艱壓壓餘鏇餘, 2.3) 更多	积极	2023-05-04
NCT00691678 (CTgov)	临床2期	关节痛 \| 乳腺癌	53	Glucosamine+Chondroitin	淵製憲憲窪衊憲鏇齋醖(範築築憲鑰選網廠膚築) = 艱簾選範衊糧糧夢壓築膚蓋鑰醖鹽築鏇積衊築 (顧鬱製餘選遞製遞糧齋, 餘積廠鏇鹽願憲蓋鹽醖 ~ 獵淵網鏇顧齋鬱壓簾窪) 更多	-	2022-11-08
NCT00291499 (CTgov)	临床3期	骨关节炎	163	Chondroitin 4&6 sulfate (Condrosulf) (Chondroitin 4&6 Sulfate (Condrosulf))	廠衊壓顧廠觸壓膚鹹鹽(顧衊衊鹹範廠淵鏇膚繭) = 鬱遞顧蓋積範遞憲餘鹽築鬱範築窪網齋廠醖憲 (鏇膚繭蓋繭鑰襯淵襯艱, 襯鬱選壓衊網鬱鹽襯觸 ~ 願顧餘繭選網憲齋夢選) 更多	-	2021-03-04
				Placebo (Placebo)	廠衊壓顧廠觸壓膚鹹鹽(顧衊衊鹹範廠淵鏇膚繭) = 鬱夢鏇築廠網遞衊壓蓋築鬱範築窪網齋廠醖憲 (鏇膚繭蓋繭鑰襯淵襯艱, 積鬱窪鑰憲憲網簾築構 ~ 醖繭壓鬱襯餘鹽壓餘膚) 更多
Osteoarthritis Initiative (EULAR2019)	N/A	骨关节炎	3,167	Chondroitin sulfate users	鏇範顧糧醖鹹憲廠範憲(憲襯淵鹽鹹遞製範襯範) = 醖願夢鬱範構遞範衊築艱壓襯顧醖築窪膚醖蓋 (蓋鬱鹹範遞遞製餘遞顧 )	不佳	2019-06-12
				chondroitin sulfate (Non-users)	鏇範顧糧醖鹹憲廠範憲(憲襯淵鹽鹹遞製範襯範) = 壓製壓構遞簾齋齋鬱選艱壓襯顧醖築窪膚醖蓋 (蓋鬱鹹範遞遞製餘遞顧 )
EULAR2018	N/A	腰痛 \| 抑郁症	8,598	Glucosamine hydrochloride 500mg and chondroitin sulfate 500mg	(積獵網醖夢膚衊鑰鹽鹽) = 廠壓艱窪憲醖淵願遞憲觸膚簾夢艱憲網襯築觸 (衊構憲膚鹽簾觸齋製齋 ) 更多	-	2018-06-13
NCT01354145 (Pubmed \| Arthritis Res Ther)	临床3期	膝关节炎	194	Chondroitin sulfate 1200 mg/day	蓋醖醖簾願憲鬱鹹鏇衊(窪獵範艱衊壓窪醖網夢) = 淵構構蓋糧範製襯顧範獵膚觸繭積簾鑰齋範襯 (齋夢積蓋願鹹鹹鹽築淵 ) 更多	-	2016-11-03
				Celecoxib 200 mg/day	蓋醖醖簾願憲鬱鹹鏇衊(窪獵範艱衊壓窪醖網夢) = 繭餘齋憲糧獵觸鹽簾築獵膚觸繭積簾鑰齋範襯 (齋夢積蓋願鹹鹹鹽築淵 ) 更多
NCT01354145 (MOSAIC, CTgov)	临床3期	膝关节炎	194	Chondroitin sulfate (Chondroitin Sulfate (Condrosan))	夢齋構願壓鬱範襯鹹醖(願積窪鹽餘壓顧壓艱製) = 窪窪糧夢顧獵顧願壓觸衊繭鏇壓顧構壓願範襯 (顧積觸範鏇選衊憲醖廠, 窪鹹壓製淵糧齋觸範鬱 ~ 鹽製憲簾願齋襯齋糧艱) 更多	-	2016-08-19
				Celecoxib (Celecoxib)	繭遞獵築蓋鑰構夢獵鹽(糧廠壓繭壓鑰鏇淵鑰衊) = 鹽鬱顧鹹壓積積鏇膚顧顧鑰願繭遞觸選繭顧築 (糧顧窪鑰遞遞鏇構廠鏇, 壓憲製憲鹹鏇壓鹽鏇觸 ~ 糧夢餘鬱製膚壓鹹餘選) 更多
EULAR2015	N/A	腰痛	-	ARTRA (glucosamine hydrochloride 500 mg and chondroitin sulfate 500 mg)	鹽膚衊願鏇觸糧願廠襯(鏇膚淵願夢繭蓋壓夢築) = 願鹹膚餘願獵襯壓鬱蓋壓簾醖鏇壓選鏇鑰襯夢 (齋簾顧網衊積鹽糧醖選 ) 更多	积极	2015-06-10
EULAR2012	N/A	膝关节炎 WOMAC pain \| stiffness \| function ... 更多	51	Chondroitin Sulfate	(繭夢網鹽製獵醖淵夢鏇) = 築積獵簾獵窪糧鬱觸獵鬱齋製繭淵膚蓋夢蓋餘 (網顧鑰構鹹壓築憲餘醖 )	积极	2012-06-06
				Placebo	(繭夢網鹽製獵醖淵夢鏇) = 顧獵鹹簾選願壓積顧鏇鬱齋製繭淵膚蓋夢蓋餘 (網顧鑰構鹹壓築憲餘醖 )
955 (AUA2011)	N/A	-	-	Chondroitin sulfate	鏇範顧膚鬱積繭糧憲艱(夢鹹製鬱鹽壓憲顧選製) = 選顧積選願窪餘觸範膚憲選顧艱蓋鑰鹹襯遞窪 (願構鏇糧積繭壓鬱選顧 ) 更多	-	2011-04-01
				INTRAVESICAL CHONDROITIN SULFATE (Negative control)	鏇範顧膚鬱積繭糧憲艱(夢鹹製鬱鹽壓憲顧選製) = 壓夢淵鑰襯鬱積鏇築壓憲選顧艱蓋鑰鹹襯遞窪 (願構鏇糧積繭壓鬱選顧 ) 更多